Filing summary
Identity and period discrepancy: The request identifies BioVie Inc. and “2014 Q3,” but the supplied filing is for NanoAntibiotics, Inc., for the unaudited quarter and nine months ended March 31, 2015. The summary below reflects the supplied filing, not BioVie Inc.
Business context and reporting period
NanoAntibiotics describes itself as an early-stage biotechnology company developing antibiotic candidates for resistant bacterial infections. Its compounds have been studied only in cell-based, in-vitro assays; the filing says animal efficacy and toxicity studies have not been conducted. The company reported no products for sale or revenue. Research and development was on hold while it negotiated potential nanotechnology licenses. The filing covers the three and nine months ended March 31, 2015, with comparative periods in 2014.
Financial performance and position
| Metric | Period or date | Reported value | Comparison |
|---|---|---|---|
| Revenue | Three and nine months ended March 31, 2015 | $0 | $0 in both comparable 2014 periods |
| Operating expenses | Three months ended March 31 | $49,042 in 2015 | $48,171 in 2014 |
| Operating expenses | Nine months ended March 31 | $178,523 in 2015 | $149,036 in 2014 |
| Net loss | Three months ended March 31 | $48,954 in 2015 | $48,041 in 2014 |
| Net loss | Nine months ended March 31 | $178,215 in 2015 | $148,660 in 2014 |
| Net cash used in operations | Nine months ended March 31 | $54,329 in 2015 | $160,441 in 2014 |
| Cash | March 31, 2015 | $278,535 | $332,864 at June 30, 2014 |
| Current liabilities | March 31, 2015 | $283,231 | $161,475 at June 30, 2014 |
With no revenue, gross margin is zero and a meaningful operating margin is not available. Nine-month research and development expense was $3,400, down from $49,419 in 2014; the company reported no R&D expense for the latest quarter. Nine-month payroll expense was $121,562 and professional fees were $42,139. Accrued payroll was $282,581 at March 31, 2015. The filing reports no interest expense, no cash interest paid, and no debt balance. Stockholders’ deficit was $1,196. The company had 87,210,000 common shares outstanding at March 31, 2015.
Changes, outlook, and risks
- Nine-month net loss increased by $29,555 from the 2014 comparable period, while operating expenses increased by $29,487. Management attributed the pause in R&D to negotiations over licensing rights; lower R&D spending was partly offset by payroll and professional fees.
- Management estimated planned spending for the next 12 months of $575,000 for R&D, $100,000 for corporate overhead, $100,000 for licensing and capital costs, and $180,000 for officer and staffing costs. The R&D estimate includes $500,000 contingent on licensing technologies under review. Management said approximately $600,000 of additional net financing was needed to meet its budget.
- The company said existing cash was expected to cover operating and capital requirements only until June 30, 2015, and that funds were insufficient for planned activity over the following 12 months. Management warned that failure to obtain financing could require curtailing development, seeking partners or licenses, selling the company, ceasing operations, or bankruptcy. The filing identifies substantial doubt about the company’s ability to continue as a going concern.
- Funding plans include equity or debt financing, licensing or sale of intellectual property, partnerships, or similar transactions; there is no assurance financing will be available. The filing also notes the company’s limited drug-development experience and risks related to development, regulation, commercialization, funding, and execution.
- Five million Series A warrants remained outstanding, exercisable at $0.50 per share for five years; exercise is a potential, not committed, funding source. The company also disclosed a five-year office lease beginning January 1, 2014, with monthly payments of $357.
- Disclosure controls and procedures were reported ineffective as of March 31, 2015. Management reported no material change in internal control over financial reporting during the quarter. No material legal proceedings were reported.
Important facts for investors to verify
- Confirm the issuer and reporting period: the supplied filing is NanoAntibiotics, Inc.’s March 31, 2015 Form 10-Q, not a BioVie Inc. filing or a 2014 Q3 report.
- Verify the status, terms, and timing of prospective licensing negotiations and whether R&D has resumed; the filing says development was on hold.
- Assess the company’s ability to raise the stated approximately $600,000 in additional financing, the detailed spending assumptions, and the cash runway.
- Review the going-concern disclosure, accrued payroll balance, and the consequences if financing is unavailable.
- Confirm scientific and regulatory progress: the reported candidates had only in-vitro testing, with no animal studies disclosed.
- Review the basis for management’s ineffective-controls conclusion and any subsequent remediation or financing developments.